Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | Hematology, Transfusion and Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137920302431 |